Skip to Content
  • Cancer

    Spreading Cancer (Or Just Waking It Up)

    If you look at any collection of “common myths about cancer”, you will probably find reassurances about the idea that having cancer surgery might cause the cancer to spread to other parts of the body. I remember coming across this one some years ago being surprised – I’d never heard that one myself, but it… Read More
  • Analytical Chemistry

    Mirror Proteins Come Through

    You know, chemistry is kind of a big field. I say that because I’ve been actively reading the chemical literature for over thirty years now, and I still keep running across topics that I never knew existed. One of these popped up the other day: racemic protein crystallography. Now there may be a few readers… Read More
  • Drug Assays

    Pharmacokinetic Advice from Merck’s Collection

    Here’s a solid med-chem paper from Merck on the topic of extending half-life for small-molecule drugs. This obviously is most important (and can have the biggest effect) if your compound has a short half-life after dosing to begin with (and plenty of compounds do). As the paper notes, if you have constant clearance for the… Read More
  • Chemical News

    More Thoughts of George Whitesides – And of Phil Baran

    The other day I wrote up some comments about a recent article from George Whitesides. If you’ve heard him speak on the topic of organic synthesis, you’ve probably heard most of what’s in that piece, but it’s a good summary of his position. Picked up roughly where I left off last time, he has this… Read More
  • Clinical Trials

    Tighten Up Your Numbers!

    There’s clearly something wrong with the way that statistics get handled and interpreted in scientific studies, and there have been many warnings. But change in this area is a hard thing to bring about. Biocentury has a good interview with someone who can tell you about that, John Ioannidis, of scientific reproducibility fame. He’s rec… Read More
  • Chemical News

    The Thoughts of George Whitesides, Part I

    A number of readers have mentioned this new paper by George Whitesides on organic synthesis. I can state as a fact that the first time I heard a joking reference to his attitude towards traditional synthetic organic chemistry was in the summer of 1983, so it’s not like he’s been keeping his thoughts bottled up. Read More
  • Alzheimer's Disease

    Bad Investments

    Here are some sequels to stories I’ve written about here, things that have had some new chapters added to them. First off, this 2015 post mentions the steep drop in shares of Clovis Biotechnology, brought on by a rather sudden revision in the announced clinical performance of their lead drug (the covalent kinase inhibitor rociletinib). Well… Read More
  • Chemical Biology

    21st Century Enzymes

    Here’s a remarkable paper that shows how enzymes can be engineered to turn out some very unnatural-looking structures. Frances Arnold’s group at CalTech has published on some work in this area in the past, and this latest variation is something t0 see. They’ve been working with various heme proteins, since that reactive center is… Read More
  • Cancer

    IDO Inhibitors Hit a Wall

    Friday brought some very unwelcome news in oncology. I’ve written about IDO inhibitors before, partly in the context of an odd situation between Incyte and Flexus, and partly in response to a recent failed trial of a compound from NewLink. That last one shook people up a bit, but (as I mentioned in the post) Read More
  • Drug Assays

    Thoughts on Compound Collections

    I’ve recently had similar questions from two different people (on two different coasts) about screening collections and compound libraries, so it seems like it could be a topic of interest. So far I have yet to come across a drug discovery organization that really thinks that its compound libraries are what they should be – Read More
123...